All randomized participants who received at least 1 dose of the trial compound (liraglutide or placebo) and who had at least 1 assessment after baseline were included in the efficacy analyses. Five participants from the liraglutide group and 1 from the placebo group were excluded from the analyses. Another participant in the liraglutide group was excluded after the first assessment and was therefore included in the efficacy analyses without completing the 16 weeks of treatment. All participants who were randomized and had received at least 1 dose of liraglutide or placebo were included in the safety analyses. BMI indicates body mass index (calculated as weight in kilograms divided by height in meters squared); HbA1c,hemoglobin A1c. To convert hemoglobin A1c to mmol/mol, subtract 2.15% and multiply by 10.929.
Plasma glucose excursion, C-peptide level, and glucagon secretion were evaluated at fixed time points before and after ingestion of oral glucose (0 indicates intake). Values represent the mean calculated by a repeated mixed-model analysis. When comparing the liraglutide group with the placebo group, the model includes the covariates age; sex; illness duration; treatment with olanzapine, clozapine, or both; baseline body mass index; and baseline Clinical Global Impressions Scale severity score. The analyses include all participants who were randomized, received at least 1 dose of the trial compound (liraglutide or placebo), and had at least 1 assessment after baseline. To convert C-peptide to nanomoles per liter, multiply by 0.331; glucagon to nanograms per liter, multiply by 1.0; and glucose levels to millimoles per liter, multiply by 0.0555.
eTable 1. Inclusion and Exclusion Criteria
eTable 2. Additional Baseline Characteristics
eTable 3. Additional Change in End Points Between Baseline and Week 16
eTable 4. Prevalence of the Most Common Adverse Events During the 16 Weeks
eTable 5. Sensitivity Analyses of the Plasma Glucose Excursion, C-Peptide, and Glucagon Secretion During the Oral Glucose Tolerance Test Between Baseline and Week 16
eTable 6. Sensitivity Analyses for the Secondary End Points Between Baseline and Week 16
eTable 7. Mean Changes for the Major Outcomes Between Baseline and Week 16 by Olanzapine and Clozapine Treatment
eTable 8. Mean Changes for the Major Outcomes Between Baseline and Week 16 by Change in Dose of Olanzapine or Clozapine
eTable 9. Mean Changes for the Major Outcomes Between Baseline and Week 16 by the 2-Hour Value During the OGTT
eMethods. Data Analysis
eFigure 1. Baseline Oral Glucose Tolerance Test for the Liraglutide and the Placebo Groups
eFigure 2. Exploratory Analyses for the Primary Outcome
Customize your JAMA Network experience by selecting one or more topics from the list below.
Larsen JR, Vedtofte L, Jakobsen MSL, et al. Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2017;74(7):719–728. doi:10.1001/jamapsychiatry.2017.1220
Can the glucagon-like peptide-1 receptor agonist liraglutide reduce body weight and improve cardiometabolic disturbances in antipsychotic-treated patients?
In this randomized clinical trial of 103 patients with schizophrenia spectrum disorders treated with clozapine or olanzapine, glucose tolerance improved significantly and 30 liraglutide-treated patients with prediabetes (63.8%) developed normal glucose tolerance compared with 8 placebo-treated patients (16.0%). Liraglutide induced a placebo-subtracted body weight loss of 5.3 kg.
Glucagon-like peptide-1 receptor agonists offer a novel and effective approach to mitigation of some of the cardiometabolic adverse effects associated with the commonly used and efficacious antipsychotic drugs clozapine and olanzapine.
Compared with the general population, patients with schizophrenia have a 2- to 3-fold higher mortality rate primarily caused by cardiovascular disease. Previous interventions designed to counteract antipsychotic-induced weight gain and cardiometabolic disturbances reported limited effects.
To determine the effects of the glucagon-like peptide-1 receptor agonist liraglutide added to clozapine or olanzapine treatment of schizophrenia spectrum disorders.
Design, Setting, and Participants
This randomized clinical double-blind trial enrolled participants at 2 clinical sites in Denmark. Of 214 eligible participants with a schizophrenia spectrum disorder, 103 were randomized to liraglutide or placebo. Participants received stable treatment with clozapine or olanzapine, were overweight or obese, and had prediabetes. Data were collected from May 1, 2013, through February 25, 2016.
Treatment for 16 weeks with once-daily subcutaneous injection of liraglutide or placebo. Trial drug therapy was titrated during the first 2 weeks of the study.
Main Outcomes and Measures
The primary end point was change in glucose tolerance estimated by a 75-g oral glucose tolerance test result. Secondary end points included change in body weight and cardiometabolic parameters.
Of the 103 patients undergoing randomization (60 men [58.3%] and 43 women [41.7%]), 97 were included in the efficacy analysis, with a mean (SD) age of 42.5 (10.5) years and mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) of 33.8 (5.9). The liraglutide and placebo groups had comparable characteristics (mean [SD] age, 42.1 [10.7] vs 43.0 [10.5] years; 30 men in each group; mean [SD] body mass index, 33.7 [5.1] vs 33.9 [6.6]). A total of 96 randomized participants (93.2%) completed the trial. Glucose tolerance improved in the liraglutide group compared with the placebo group (P < .001). Altogether, 30 liraglutide-treated participants (63.8%) developed normal glucose tolerance compared with 8 placebo-treated participants (16.0%) (P < .001; number needed to treat, 2). Body weight decreased with liraglutide compared with placebo (−5.3 kg; 95% CI, −7.0 to −3.7 kg). Reductions in waist circumference (−4.1 cm; 95% CI, −6.0 to −2.3 cm), systolic blood pressure (−4.9 mm Hg; 95% CI, −9.5 to −0.3 mm Hg), visceral fat (−250.19 g; 95% CI, −459.9 to −40.5 g), and low-density lipoprotein levels (−15.4 mg/dL; 95% CI, −23.2 to −7.7 mg/dL) occurred with liraglutide compared with placebo. Adverse events with liraglutide affected mainly the gastrointestinal tract.
Conclusions and Relevance
Liraglutide significantly improved glucose tolerance, body weight, and cardiometabolic disturbances in patients with schizophrenia spectrum disorders treated with clozapine or olanzapine.
clinicaltrials.gov Identifier: NCT01845259
Patients with schizophrenia have a 2- to 3-fold higher mortality compared with the general population.1-3 Somatic diseases, primarily cardiovascular disease, account for an estimated 60% of the excess mortality.3,4 A high prevalence of obesity, metabolic disturbances, and type 2 diabetes among patients with schizophrenia largely explains the increased risk for cardiovascular morbidity and increased mortality.3-5 Antipsychotic medications are effective for treating schizophrenia6 but also induce weight gain, metabolic disturbances, and type 2 diabetes.7,8 Clozapine and olanzapine are 2 of the most effective antipsychotics, and clozapine is used for treatment-resistant schizophrenia.9 Unfortunately, clozapine and olanzapine induce the greatest weight gain and confer a higher risk for metabolic disturbances compared with all other psychotropic medications.5,7 Clozapine and olanzapine are associated with increased appetite and delayed satiety signaling and sedation, which can lead to body weight gain and an increased risk for metabolic disturbances.5,8 Previous studies have demonstrated limited effects for counteracting antipsychotic-induced weight gain with adjunct pharmacologic treatments, behavioral interventions, or switch of antipsychotics.10-14
Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted from the L cells in the intestinal mucosa in response to nutrients.15 Glucagon-like peptide-1 stimulates insulin secretion and inhibits glucagon secretion, thereby lowering plasma glucose levels.15 In 2009, the GLP-1 receptor agonist liraglutide (1.8 mg once daily) was approved for treatment of type 2 diabetes.16 In 2015, a high dose of liraglutide (3 mg once daily) was approved for treatment of obesity owing to its inhibitory effects on appetite and food intake.15,17-20
Quiz Ref IDThe potential mitigating effects of GLP-1 receptor agonists in antipsychotic-treated patients require further elucidation.21-24 The present trial investigated the effect of 1.8 mg of liraglutide once daily added to stable treatment with clozapine or olanzapine in patients with a schizophrenia spectrum disorder (schizoaffective disorder excluded) who were overweight or obese and had prediabetes.
This investigator-initiated randomized clinical trial was conducted from May 1, 2013 (first patient, first visit), through February 25, 2016 (last patient, last visit), at 2 clinical sites in Denmark. A copy of the study protocol is found in Supplement 1, and details have been published previously.25 The trial was approved by the Scientific-Ethical Committee of the Capital Region of Denmark and the Danish Health Authority and conducted in accordance with the Declaration of Helsinki26 and Good Clinical Practice. Before participants underwent examination, they were provided oral and written information and gave written informed consent.
Eligible participants were adults aged 18 to 65 years who were receiving stable treatment with clozapine or olanzapine and diagnosed with a schizophrenia spectrum disorder (schizoaffective disorder excluded) according to The ICD-10 Classification of Mental and Behavioural Disorders: Clinical Descriptions and Diagnostic Guidelines27 or DSM-IV-TR.28 Furthermore, the participants had prediabetes and a body mass index (BMI; calculated as weight in kilograms divided by height in meters squared) of 27 or greater. Prediabetes was defined as an elevated fasting plasma glucose level of 110 to 125 mg/dL (to convert to mmol/L, multiply by 0.0555), elevated glycated hemoglobin level of 6.1% to 6.4% (to convert to mmol/mol, subtract 2.15% and multiply by 10.929), and/or impaired glucose tolerance with a 2-hour plasma glucose level of at least 140 mg/dL during a 75-g oral glucose tolerance test. Main exclusion criteria consisted of type 2 diabetes (glycated hemoglobin level of at least 6.5%), treatment with antidiabetic medications, substance abuse, or serious somatic illnesses (eg, pancreatitis or heart disease). A detailed list of all inclusion and exclusion criteria is presented in eTable 1 in Supplement 2.
At baseline and after 16 weeks of treatment, all participants completed a 4-hour, 75-g oral glucose tolerance test. Blood samples were obtained using a cannula inserted in an antecubital vein before oral intake of the glucose load and at specific times thereafter (15 and 10 minutes before intake; at intake ; and 5, 10, 15, 20, 30, 40, 50, 60, 90, 120, 150, 180, and 240 minutes after intake). Blood samples were analyzed for plasma levels of glucose, C-peptide, and glucagon. A glucose oxidase method using a glucose analyzer (2300 Stat Plus analyzer; YSI Inc) measured plasma glucose levels. Whole blood samples were distributed in serum tubes containing a clot activator and chilled tubes containing EDTA. To prevent degradation, a dipeptidyl peptidase 4 inhibitor (valine pyrrolidide) was added to the EDTA-containing tubes, with a final concentration of 0.01 mmol/L. The serum samples were left to coagulate at room temperature. The plasma and serum samples were stored at −20°C and −80°C, respectively. Analyses of C-peptide and glucagon were performed using a 2-sided electrochemiluminescence immunoassay (ADIVA Centaur XP; Siemens) and a C-terminal glucagon-specific antibody (code No. 4305).29
After completing the oral glucose tolerance test, body composition was evaluated using dual-energy x-ray absorptiometry (DXA), and 4 rating scales were administered. The DXA measured body composition by subdividing the soft tissue into fat and lean subcompartments.30,31 A scanner (Lunar Prodigy; GE Healthcare) with Encore software (version 16) was used. The CoreScan software option (GE Healthcare) was applied to calculate the amount of visceral fat in the android region from the level of the iliac crest up to 20% of the distance to the chin.32 The rating scales evaluated (1) quality of life (the Schizophrenia Quality of Life Scale),33 (2) illness severity (Clinical Global Impressions Scale severity score),34 (3) daily functioning (Global Assessment of Functioning scale),35 and (4) alcohol consumption (Alcohol Use Disorders Identification Test).36
Quiz Ref IDAfter the baseline examinations, eligible participants were randomly assigned in a double-blind manner to 16 weeks of treatment with subcutaneously injected liraglutide or placebo provided in prefilled pen injectors. The participants followed a fixed uptitration schedule of 0.6 mg per week to a daily dose of 1.8 mg. Participants who did not tolerate uptitration to 1.8 mg of liraglutide continued to receive 1.2 mg/d (n = 3). Every 4 weeks from the day of randomization, participants had blood samples obtained; body weight, waist circumference, and blood pressure measured; and adverse events and alcohol consumption recorded using the Alcohol Use Disorders Identification Test.
The primary end point was change in glucose tolerance estimated from the plasma glucose excursions (all time values) after the oral glucose tolerance test from baseline to week 16. Secondary end points included changes in glycemia (fasting plasma glucose levels, impaired glucose tolerance, and glycated hemoglobin levels), body weight, waist circumference, and blood pressure; secretion of C-peptide and glucagon evaluated during the oral glucose tolerance test; beta cell function, insulin sensitivity, and beta cell function evaluated using the homeostatic model assessment 2; body composition evaluated using DXA; lipid profile; liver function; measures of quality of life and daily functioning; severity of the psychiatric disease; and alcohol consumption from baseline to the end of trial.
The study was initially designed as an exploratory study. However, before the study commenced, a sample size of 96 patients (48 in each group) was estimated based on the primary end point and values from participants with and without impaired glucose tolerance measured in a prior study (eMethods in Supplement 2).37 All statistical analyses except the post hoc sensitivity analyses were performed with treatment groups still blinded. Before dividing participants into 2 groups, the statistical analysis plan was uploaded at clinicaltrials.gov and the data set was locked. Statistical analyses were performed using SAS software (version 9.4; SAS Institute). The hypothesis tests were 2 sided, and the level of significance was 5%. All efficacy analyses were performed using a modified intention-to-treat principle in which all randomized participants who received at least 1 dose of the trial compound and had at least 1 assessment after baseline were included. All safety analyses were performed in an intention-to-treat sample in which all randomized participants who received at least 1 dose of the trial compound were included. For the primary end point, a repeated mixed-model analysis of covariance was used to analyze change in glucose tolerance from week 0 to week 16 for the liraglutide and the placebo groups. All changes in secondary end points from baseline to the end of the trial were analyzed using repeated mixed-model analyses for continuous outcomes and mixed-model logistic regression for categorical outcomes. To adjust for multiple testing, the Bonferroni correction was applied. For comparison between the 2 groups, the covariates age, sex, illness duration, treatment group (olanzapine, clozapine, or both), and baseline Clinical Global Impressions Scale severity score and BMI were included in the analyses together with the baseline value of the relevant variable. Exploratory analyses and post hoc sensitivity analyses (eMethods and eTables 2-9 in Supplement 2) were performed to assess the robustness of the primary analyses. The number needed to treat for normalization of prediabetes status was calculated dividing 1 by the risk difference. Effect sizes (Cohen d) for lowering glycated hemoglobin levels and reducing body weight were calculated by dividing the difference of the means in change from baseline to end point (treatment − placebo) by the pooled SD.
Of 214 eligible participants with a schizophrenia spectrum disorder, 103 (60 men [58.3%] and 43 women [41.7%]; mean [SD] age, 42.5 [10.5] years) were randomized to liraglutide or placebo treatment (Figure 1). One participant in each group withdrew from the trial. In the liraglutide group, an additional 3 participants were randomized in error and 1 participant died before the end of the study (Figure 1). These participants withdrew from the study before any follow-up visits were conducted and therefore were not included in the efficacy analyses. One participant with follow-up data until week 12 (excluded owing to a large clozapine dose reduction) was included in the efficacy analyses (Figure 1). Quiz Ref IDAltogether, 96 participants (93.2%) completed the trial (Figure 1), including 46 of the 52 participants (88.5%) randomized to liraglutide and 50 of the 51 participants (98.0%) randomized to placebo (P = .11). The randomization resulted in comparable groups at baseline (Table 1 and eTable 2 and eFigure 1 in Supplement 2).
After 16 weeks of treatment, the primary end point of glucose tolerance evaluated by the oral glucose tolerance test improved significantly for liraglutide compared with placebo (P < .001) (Figure 2). A 23% larger reduction of the 2-hour plasma glucose level during the oral glucose tolerance test occurred in the liraglutide group compared with the placebo group (0.77; 95% CI, 0.70-0.85; P < .001). The improvements in glycemic control were robust in sensitivity analyses, examining (1) no covariate adjustments (P < .001) and (2) all randomized patients (n = 103) included and assumed to have no change in values from baseline to week 16 in the 6 patients with no postbaseline assessments (P < .001) (eTable 5 in Supplement 2). Quiz Ref IDIn the liraglutide group, 30 participants (63.8%) changed status from prediabetes to normal glucose tolerance compared with 8 (16.0%) in the placebo group, corresponding to a number needed to treat of 2 (Table 2). The liraglutide group had significantly reduced glycated HbA1c level (−0.2%; 95% CI, −0.3 to −0.1%; P < .001) and relative change in fasting plasma glucose level (0.90; 95% CI, 0.88 to 0.95; P < .001) compared with the placebo group (Table 2). An increased C-peptide secretion and a decreased glucagon secretion during the oral glucose tolerance test was found with liraglutide compared with placebo (C-peptide, P = .01; glucagon, P = .01). After adjusting for covariates, the differences in the oral glucose tolerance test results were no longer significant for C-peptide (P = .06) or glucagon secretion (P = .13) (Figure 2 and eTable 5 in Supplement 2). With use of the homeostatic model assessment 2 model, an improved beta cell function for the liraglutide group was found, but no change in insulin sensitivity occurred (Table 2).
At week 16, the mean weight loss difference between liraglutide and placebo treatment was −5.3 kg (95% CI, −7.0 to −3.7 kg). Compared with placebo, mean differences for liraglutide compared with placebo were significant for reduced waist circumference (−4.1 cm; 95% CI, −6.0 to −2.3 cm; P < .001), BMI (−1.8; 95% CI, −2.4 to −1.3; P < .001), systolic blood pressure (−4.9 mm Hg; 95% CI, −9.5 to −0.3 mm Hg; P = .04), and levels of total cholesterol (−19.3 mg/dL; 95% CI, −30.9 to −7.7 mg/dL; P < .001) and low-density lipoprotein cholesterol (−15.4 mg/dL; 95% CI, −23.2 to −7.7 mg/dL; P < .001). Furthermore, liraglutide reduced visceral fat (−250.19 g; 95% CI, −459.9 to −40.5 g; P = .02) and caused a reduction of total body fat (relative change, 0.96; 95% CI, 0.94 to 0.99; P = .01) evaluated by the DXA scan (Table 2). With the exception of systolic blood pressure and body composition measures, these changes remained significant after Bonferroni correction and in sensitivity analyses (eTable 6 in Supplement 2). Effect size for lowering glycated hemoglobin levels was 1.0 (95% CI, 0.61 to 1.46); for reducing body weight, 1.1 (95% CI, 0.77 to 1.64).
No differences were found regarding liver function, but a small, significant increase of amylase level (1.27 vs 0.98 U/L [to convert to microkatals per liter, multiply by 0.0167; P < .001) was found in the liraglutide group (eTable 3 in Supplement 2). The most common adverse events with liraglutide were related to the gastrointestinal tract, and rates were high in both groups (Table 3) and most prevalent at the beginning of treatment. The nausea rate was significantly higher in the liraglutide group (31 of 50 [62%] vs 16 of 50 [32%]; P = .008) but diminished over time (eTable 4 in Supplement 2). No effect of nausea with respect to body weight reduction, BMI, waist circumference, and reduction of visceral fat was found in subgroup analyses comparing participants who reported nausea with those who did not. Quiz Ref IDFewer serious adverse events occurred in the liraglutide group compared with the placebo group (6 of 51 [11.5%] vs 13 of 51 [25.5%]). No difference in the occurrence of somatic serious adverse events was found (Table 3). The most common serious adverse event was exacerbation of the psychiatric disease and voluntary admission to a psychiatric hospital. No differences were found between liraglutide and placebo with respect to quality of life, daily function, psychiatric disease severity, or alcohol intake (Table 2 and eTable 3 in Supplement 2).
In overweight or obese patients with schizophrenia spectrum disorders and prediabetes, 16 weeks of liraglutide as an adjunctive treatment to stable treatment with clozapine or olanzapine significantly improved glucose tolerance and glycemic control. At the end of the trial, the placebo-subtracted body weight loss was 5.3 kg. The weight loss was further supported by concurrent reductions in waist circumference and visceral fat evaluated using DXA. These reductions are particularly relevant because increased waist circumference and visceral fat accumulation are strongly associated with insulin resistance, diabetes development, and consequent cardiovascular disease.38 Compared with placebo, liraglutide reduced body weight and lowered glycated hemoglobin levels with large effect sizes of 1.0 and 1.1, respectively, and improved several cardiometabolic variables, including systolic blood pressure and total and low-density lipoprotein cholesterol levels. Consistent with the proposed mechanisms of liraglutide for improving glycemic control,15 increased levels of C-peptide and suppressed levels of glucagon in the liraglutide group were found. Homeostatic model assessment 2 calculations indicated an increased beta cell function; however, no improvement in insulin resistance or insulin sensitivity occurred.
Although the participants included in this study received ongoing treatment with antipsychotic compounds,8,39 the improvements induced by liraglutide were consistent with the findings of previous studies in individuals with no known psychiatric illness.17,18,40 Adverse events in the liraglutide group were similar to those previously described in individuals without schizophrenia spectrum disorders.17,18,20,40 Most adverse events were transient gastrointestinal tract effects, particularly nausea.20,40 The higher nausea rate in the liraglutide group was not associated with a larger body weight reduction. One participant, a man in his 60s with a long duration of schizophrenia, died unexpectedly after 3 days of acute illness. No causal relationship was established to treatment with liraglutide. Altogether, the liraglutide group experienced significantly fewer serious adverse events, with exacerbation of patients’ psychiatric disease being the most common cause, and no differences in quality of life, daily functioning, or psychiatric disease severity were found.
Other interventions for antipsychotic-induced weight gain and metabolic disturbances have been examined previously.10-14 Several meta-analyses of adjunct pharmacologic intervention to antipsychotic medications found metformin hydrochloride to be superior to placebo and more effective than comparators,10,13,14,41 but metformin only induced a body weight loss of approximately 3 kg for 2 to 4 months.10,13,14 In meta-analyses of other interventions, such as adjunctive treatment with topiramate,42,43 switch of antipsychotic medication,12 and behavioral interventions,11 similar or somewhat smaller effects on antipsychotic-induced body weight gain and less consistent improvements across metabolic parameters were found.
Most antipsychotic-treated patients experience weight gain and metabolic disturbances,7,8 although large interindividual differences exist.44 In this trial, a selected group of patients treated with the antipsychotic compounds clozapine or olanzapine were included, which could be viewed as a limitation. Clozapine and olanzapine were selected because they induce the greatest weight gain and metabolic abnormalities.8,39 Furthermore, because clozapine and olanzapine are among the most efficacious antipsychotic compounds,6 switch to other antipsychotics is often not possible.8,9,12 The participants also fulfilled criteria for prediabetes, which further limits generalizability. However, prediabetes is considered to be a strong predictor for later development of diabetes and is associated with an increased risk for cardiovascular disease.45,46 In the present study, only participants with a glycated hemoglobin level of at least 6.5% were characterized as having type 2 diabetes,46 allowing participants with a 2-hour glucose level greater than 199 mg/dL during the oral glucose tolerance test to be included in the study. However, in sensitivity analyses in which these participants (n = 24) were excluded, the significant effects of liraglutide persisted (eFigure 2 and eTable 9 in Supplement 2).
Strengths of the study include the randomized, placebo-controlled design and double-blinding of treatment.25 Although the participants had a severe mental illness, had to accept daily subcutaneous injection, and had relatively high rates of nausea, the dropout rate remained very low (7 participants [6.8%]) compared with previous reports of nonpsychiatric populations treated with liraglutide.18 In our study, participants were treated with stable doses of clozapine or olanzapine for more than 6 months before inclusion. Because antipsychotic-induced weight gain and metabolic disturbances are most profound at the beginning of treatment,8,39 further research is needed to determine whether liraglutide can be used as a preventive adjunctive treatment during the emergence of weight gain and metabolic abnormalities. Furthermore, a head-to-head study with the best-studied comparator for this purpose (metformin or topiramate) would be relevant.10,13,14,43 Last, several GLP-1 receptor agonists are currently available for the treatment of type 2 diabetes,16 and 1 randomized clinical trial24 recently reported that the once-weekly GLP-1 receptor agonist exenatide did not promote weight loss or improve metabolic disturbances in antipsychotic-treated patients. However, the number of participants was small and the intervention period was short. Further research is also needed to determine the safety and effectiveness of different GLP-1 receptor agonists in antipsychotic-treated patients. Whether the recently established benefits of liraglutide treatment for cardiovascular disease47 can be extended to patients with schizophrenia spectrum disorder is beyond this study to establish; however, the results of the present study are encouraging.
In patients with schizophrenia spectrum disorder, once-daily subcutaneous injection with the GLP-1 receptor agonist liraglutide as adjunctive treatment to clozapine or olanzapine was a safe and effective pharmacologic intervention. Liraglutide improved glucose tolerance and metabolic variables and induced a body weight loss superior to that of placebo without adversely affecting the mental status of the participants.
Corresponding Author: Anders Fink-Jensen, DMSc, Psychiatric Centre Copenhagen, University of Copenhagen, Edel Sauntes Alle 10, DK-2100 Copenhagen O, Denmark (email@example.com).
Accepted for Publication: April 13, 2017.
Published Online: June 10, 2017. doi:10.1001/jamapsychiatry.2017.1220
Author Contributions: Drs Fink-Jensen and Larsen had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Correll, Vilsbøll, Fink-Jensen.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Larsen.
Critical revision of the manuscript for important intellectual content: Vedtofte, Jespersen, Svensson, Koyuncu, Schjerning, Oturai, Kjaer, Nielsen, Holst, Ekstrøm, Correll, Vilsbøll, Fink-Jensen.
Statistical analysis: Larsen, Svensson, Ekstrøm.
Obtained funding: Larsen, Vilsbøll, Fink-Jensen.
Administrative, technical, or material support: Larsen, Vedtofte, Jespersen, Koyuncu, Schjerning, Oturai, Nielsen, Vilsbøll, Fink-Jensen.
Study supervision: Larsen, Vedtofte, Koyuncu, Kjaer, Correll, Vilsbøll, Fink-Jensen.
Conflict of Interest Disclosures: Dr Schjerning reports receiving speaker honoraria from Lundbeck Pharma. Dr Nielsen reports receiving speaker honoraria from Hemocue, Lundbeck, and Bristol-Myers Squibb and research grants from H. Lundbeck and Pfizer. Dr Holst reports consulting for Merck Sharp & Dohme, Novo Nordisk A/C, and Roche. Dr Correll reports consulting and/or advising or receiving honoraria from AbbVie, Acadia, Actavis, Actelion, Alexza, Alkermes, Bristol-Myers Squibb, Cephalon, Eli Lilly and Company, Forum, Genentech, Gerson Lehrman Group, IntraCellular Therapies, Janssen/J&J, Lundbeck, Medavante, Medscape, Merck Sharp & Dohme, Otsuka, Pfizer, ProPhase, Reviva, Roche, Sunovion, Supernus, Takeda, Teva, and Vanda; providing expert testimony for Bristol-Myers Squibb, Janssen, and Otsuka; serving on a data safety monitoring board for Eli Lilly and Company, Janssen, Lundbeck, Pfizer, Takeda, and Otsuka; and receiving grant support from Bristol-Myers Squibb, Otsuka, Lundbeck, and Takeda. Dr Vilsbøll reports receiving lecture fees from Amgen, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, Merck Sharp & Dohme, Novo Nordisk A/C, Sanofi, and Zealand Pharma and serving on the advisory boards of AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, Merck Sharp & Dohme, Novo Nordisk A/C, and Sanofi. Dr Fink-Jensen reports sponsoring the study and receiving an unrestricted grant from Novo Nordisk A/S. No other disclosures were reported.
Funding/Support: This study was supported by an unrestricted grant (Dr Fink-Jensen) and receipt of liraglutide and the liraglutide placebo pens from Novo Nordisk A/S, Capital Region Psychiatry Research Group, the foundation of King Christian X, and 1-year pregraduate research grants from the Lundbeck Foundation (Dr Jespersen and Ms Svensson).
Role of the Funder/Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Meeting Presentation: This paper was presented at the 77th Scientific Sessions of the American Diabetes Association; June 10, 2017; San Diego, California.
Additional Contributions: Bente Bennike, Psychiatric Centre Copenhagen, Signe Foghsgaard, Aalborg University Hospital, Susie Brøndum, Psychiatric Centre Copenhagen, Britt Marie Droob, Psychiatric Centre Copenhagen, Lene Brus Albæk, Panum Institute, University of Copenhagen, and Sonja Snel, Aalborg University Hospital, assisted in the trial as part of their employment; they did not receive special compensation.
Create a personal account or sign in to: